SPAS(SH:603168)2022-04-25 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 149,368,784.48, representing a decrease of 2.48% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 27,651,872.01, an increase of 163.64% year-on-year[4]. - Basic and diluted earnings per share were both CNY 0.09, reflecting a 200% increase year-on-year[4]. - The company's total revenue for Q1 2022 was RMB 149.37 million, down 2.6% from RMB 153.16 million in Q1 2021[18]. - The company reported a net profit of RMB 35.76 million for Q1 2022, significantly up from RMB 17.44 million in Q1 2021, representing a growth of 104.5%[18]. - Net profit for Q1 2022 reached CNY 27,651,872.01, a significant increase of 164.5% compared to CNY 10,488,392.31 in Q1 2021[21]. - Total revenue from sales in Q1 2022 was CNY 169,739,076.41, compared to CNY 160,405,215.88 in Q1 2021, indicating a year-on-year increase of 5.5%[24]. - Gross profit for Q1 2022 was CNY 79,720,903.54, with a gross margin of approximately 72.8%[31]. - Net profit for Q1 2022 was CNY 11,977,096.42, down 18.8% from CNY 14,729,764.42 in Q1 2021[31]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 30,565,574.33, up by 144.92% compared to the previous year[4]. - Operating cash flow for Q1 2022 was CNY 30,565,574.33, up from CNY 12,479,810.76 in Q1 2021, representing a growth of 144.5%[24]. - The company reported a net cash increase of CNY 120,064,081.63 in Q1 2022, compared to CNY 112,622,702.82 in Q1 2021[25]. - Cash and cash equivalents increased by 86.67%, primarily due to the maturity of financial products[6]. - Cash and cash equivalents at the end of Q1 2022 totaled CNY 258,587,877.03, an increase from CNY 219,403,276.00 at the end of Q1 2021[25]. - The company's cash and cash equivalents rose to RMB 258.59 million as of March 31, 2022, compared to RMB 138.52 million at the end of 2021, reflecting improved liquidity[14]. - Cash and cash equivalents at the end of Q1 2022 totaled CNY 221,162,932.20, an increase from CNY 213,452,718.27 at the end of Q1 2021[34]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,540,916,953.81, a decrease of 2.80% from the end of the previous year[4]. - As of March 31, 2022, the company's total assets amounted to RMB 1.54 billion, a decrease from RMB 1.59 billion at the end of 2021[15]. - The company's total current assets as of March 31, 2022, were CNY 424,319,247.74, down from CNY 544,530,868.85 at the end of 2021[28]. - The total liabilities decreased to RMB 160.80 million as of March 31, 2022, from RMB 232.89 million at the end of 2021, indicating a reduction in financial obligations[16]. - The company's equity attributable to shareholders increased to RMB 1.38 billion as of March 31, 2022, compared to RMB 1.35 billion at the end of 2021, showing a positive trend in shareholder value[16]. - Total liabilities decreased to CNY 128,116,275.65 in Q1 2022 from CNY 190,974,766.88 in Q1 2021[30]. - The total assets as of Q1 2022 were CNY 1,527,308,479.73, down from CNY 1,578,189,874.54 in Q1 2021[30]. Investments and Equity - The company reported non-recurring gains and losses totaling CNY 15,741,337.45 for the period[5]. - The company completed the transfer of 100% equity of Qiangshen Pharmaceutical, receiving an initial payment of RMB 41.82 million and settling debts of RMB 88.06 million[12]. - The company has not yet received the remaining equity payment of RMB 40.18 million and a penalty of RMB 10.39 million from the buyer of Qiangshen Pharmaceutical[12]. - Long-term equity investments increased to CNY 639,515,379.16 as of March 31, 2022, compared to CNY 590,000,000.00 at the end of 2021[28]. Research and Development - Research and development expenses increased to RMB 20.62 million in Q1 2022, up from RMB 11.64 million in Q1 2021, indicating a focus on innovation[18]. - Research and development expenses increased to CNY 20,623,127.13 in Q1 2022, up from CNY 11,617,548.86 in Q1 2021, reflecting a focus on innovation[31]. - The company is actively pursuing the consistency evaluation of the quality and efficacy of its Benzalkonium Chloride Eye Drops as per regulatory requirements[11]. Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[31].